Sanofi has returned to T-cell engager territory via an agreement to pay $180 million in the near term for a phase 1-stage trispecific antibody from Kali Therapeutics.
- Home |
- Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific
- March 23, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
